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ABSTRACT 
Most of the physiological effects of the rennin-angiotensin system (RAS) are mediated by angiotensin II (AgII) type one receptors 
(AT1R), producing cellular dedifferentiation and proliferation; vasoconstriction; renal tubule sodium (Na+) reabsorption etc. 
However, the pathophysiologic role of AgII type two receptor (AT2R) has not been clearly defined yet. This review was, therefore, 
aimed at summarizing a plenty of primary literatures related to the role of AT2R. AT2R is a special G protein coupled receptor that 
is not coupled with the usual second messengers. The expression level of AT2R is greater in the neonates and fetal ages than in 
adults though its expression is up-regulated following tissue injury in adults implicating its role in regulating cell differentiation, 
growth and inflammations. Most of the cellular actions mediated by AT2R are counter regulatory to that of AT1R. AgII produces the 
cellular effects by acting on AT2R via different signal transduction pathways. The common cellular effects mediated by AT2R are 
antiproliferative, anti-inflammatory, vasodilation, natriuresis, etc which may be essential for modulating the cardiovascular, renal 
and brain injuries caused by different etiologies. The principal molecular signal transductions mediated by AT2R involve stimulation 
of the bradykinin and/or nitric oxide-cGMP pathwy, inactivation of mitogen activated protein kinase pathway by stimulating tyrosine 
and serine/threonien phosphatses, production of the neuroprotective factors, like BDNF, etc. These signaling pathways may exert 
cardio-renal and neuroprotective functions. Therefore, the development of drugs that stimulate the AT2R may the potential target to 
promote the treatment of different disorders related to the cardiovascular, renal and brain dysfunctions. 
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The renin–angiotensin system (RAS) is a coordinated 
hormonal cascade involved in cardiovascular system 
with AgII as the main effector peptide regulating blood 
pressure.
1 
Angiotensin peptides are derived from the 
precursor protein angiotensinogen via several enzy-
matic conversion pathways as shown in the figure -1.  
The RAS has different components to produce the 
active ligands; AgII, AgIII, Ag(IV), Ag (1–7), and Ag 
(3–7). These ligands interact with several receptor 
including AT1, AT2, AT4, and Mas distributed within 
the central and peripheral nervous systems as well as 
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Figure 1: The renin-angiotensin pathway including active ligands (bold), enzymes, receptors, and inhibitors involved in the synthesis 
and ligand-receptor interaction in the different body systems.2 Abbreviations: ACE, angiotensin converting enzyme; ACE2, 
angiotensin converting enzyme 2; APA, aminopeptidase A; APN, aminopeptidase N; ARBs, angiotensin receptor blockers. 
 
Ang II binds mainly two distinct RAS receptors; AT1R 
and AT2R, with high affinity.
1,3
 The vast majority of the 
physiological actions of Ang II are mediated by AT1Rs, 
including cellular dedifferentiation and proliferation; 
vasoconstriction; reduction of vascular compliance; 
cardiac contractility; increased renal tubule sodium 
(Na
+
) reabsorption; aldosterone, vasopressin and 
endothelin secretion; salt appetite; thirst; and activation 
of the sympathetic nervous system.
1,3
 But, the 
pathophysiologic role of AT2R is not yet clear; which is 
the main target of this review. 
AT2R Expression 
The AT2R is a 7-transmembrane GPCR composed of 
363 amino acids with only 34% sequence homology 
with the AT1R. AT2Rs are expressed ubiquitously at 
very high levels in the fetus, but decline dramatically in 
the neonatal period in most, but not all, tissues. 
Although there is relatively low expression of AT2Rs 
compared to AT1Rs in adult tissues, AT2Rs are 
expressed in the adult kidney, adrenal cortex, heart and 
vasculature, and predominate over AT1Rs in specific 
sites such as the uterus, ovary, and adrenal medulla and 
in discrete areas of the brain.
1,3
 
Even though AT2R is much less abundant in adult 
tissues, it is up-regulated in pathological conditions such 
as myocardial infarction, stroke or cutaneous incisional 
wounds.
3,4
 This investigation was supported by an 
upregulation of AT2-R expression on fibroblast cells in 
failing hearts.
5
 AT2R present in the fibroblasts was 
shown to exert an inhibitory effect on Ang II–induced 
mitogen signals. 
In addition, a study done on developmental changes in 
AT1R and AT2R-protein expression in rats using 
western blot technique showed that the expression of 
AT2R was lower in both fetuses and neonates than that 
in adults in brainstem, kidney and liver and the opposite 
expression level was true for AT1R.
6 
These may indicate 
involvement of the AT2R in the physiology of adults 
and in the development and differentiation of fetal cells 
in the embryonic development stage. 
The AT2R Signaling Pathways  
The effects of AgII are mediated by a family of seven 
transmembrane receptors. In adult, the majority of the 
receptors are of the AT1R isoform, which is coupled to 
heterotrimeric G proteins (Gq). AT2 receptor couples to 
both Giα2 and Giα3 and raises the possibility that 
selective interactions between AT2R and different G 
proteins may result in specific cellular effects mediated 
by AT2 stimulation 
7
. AT2R is a non classical GPCR for 
which G protein coupling has not been demonstrated, 
but its conserved motif in the third intracellular loop 
may mediate novel intracellular effects.
8
 
 AT1R and AT2R-induced signals antagonize phosphor-
lipase C-β phosphorylation. Ang II induced AT1R 
signals may be mainly blocked by AT2R signals 
through their negative cross-talk in the cytoplasm (at 
inositol phosphate production) rather than by the hetero-
dimerization of both receptors on the cell surface. Thus, 
the proper balance of the expression levels of AT1R and 
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Roles of AT2R in cardiovascular functions 
While AT1R antagonists (ARBs) are well recognized 
and commonly used in the treatment of many 
cardiovascular disorders, the potential cardiovascular 
AT2R mediated effects are not well known. 
Role of AT2R in the control of vascular tone 
and arterial pressure 
The renin-angiotensin system is a major physiological 
regulator of body fluid volume, electrolyte balance, and 
arterial pressure. Virtually all of these actions of AgII 
have been attributed to an action at the AT1R.
10
 
Different studies have revealed that AT2R mediate 
vascular relaxation, opposing the actions of AgII on 
AT1R. 
An in vitro and in vivo study done on aortic and 
mesenteric vessels showed that AT2R stimulation by a 
non- peptide C21 causes a dose dependent vaso-
relaxation and evoked reduction in blood pressure. This 
vasorelaxation effect was abolished by AT2R 
antagonist, PD123319. The reduction of blood pressure 
was enhanced when combination of the AT1 receptor 
antagonist, candesartan, and C21 were given to 
hypertensive rats.
11
 The vasodilation of AT2R mediated 
effect has been also revealed by AT1R antagonist in the 
presence of an unopposed endogenous AgII. This 
implies that AT2R activation can facilitate the decrease 
in mean arterial pressure caused by an AT1 receptor 
antagonist, which was confirmed by the administration 




The contribution of AT2R stimulation in vasodilation 
and antihypertensive effect produced by AT1R 
antagonists has also been demonstrated in rat isolated 
mesenteric resistance arterie.
13
 The increase in 
endogenous levels of Ang II during AT1R blockade 
may also contribute for the vasorelaxation effect in the 
presence of unblocked AT2R. Similarly, a study done in 
isolated uterine artery of pregnant mice demonstrated 
that AT2 receptor-mediated vasodilatation plays a role 
in modulating Ang-II contractile responses in 
pregnancy.
14
 The possible mechanisms of AT2R 
mediated vasodilation have been studied in isolated 
uterine artery of Sprague–Dawley rats that revealed AT2 
receptor-mediated vasorelaxation via NO-cGMP 
pathway and a bradykinin (BK) B2 receptor pathway 
(Figure 2). This mechanism had been confirmed by the 
reduction in contractile response of agiotensin II on 
uterine artery in the presence of HOE 140 (BK B2 
antagonist), and No-nitro-L-arginine (NOLA) (NOS 
inhibitor).
15
 Another study demonstrated that stimulation 
of AT2 receptors caused a significant vasodilation 
through local production of BK in resistant arteries of 
rat mesentery in a flow-dependent manner.
16
 This effect 
had been shown by comparing the vasodilation response 
in kininogen negative rat with that of the wild one.  
Moreover, another study demonstrated that AgII 
mediates renal production of BK, which, in turn, 
releases nitric oxide and cGMP via stimulation of AT2 
receptors. The authors also suggested that the increase in 
blood pressure and the decrease in renal BK, nitric 
oxide, and cGMP during AT2R blockade indicate the 
roles of the AT2R in mediating the counter regulatory 
vasodilation effect in hypertension and prevention of a 
further increase in blood pressure.
10
 In addition, chronic 
infusion of C21 decreased nocturnal norepinephrine 
(NE) excretion and blood pressure via a nNOS/NO 




Figure 2: Putative mechanism underlying AT2R’s function in cardiovascular diseases.18 Abbreviations:- AT2R, AgII Type-2 
Receptor; AT1R, AgII Type-1 Receptor; ARBs, Angiotensin Receptor Blockers; B2R, Bradykinin B2 Receptor; Gαi, G protein; NO, 
Nitric Oxide; cGMP, 3'-5'-cyclic guanosine monophosphate; NE, Norepinephrine; PP2A, Protein phosphatase 2A; MAPK, Mitogen-
activated Protein Kinase; SHP-1, Src homology region 2 domain containing phosphatase; ERK1/2, Extracellular signal-regulated 
kinases 1 and 2 
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Effect of AT2Rs in the control of 
cardiovascular structure 
Both circulating and locally generated Ag II has 
contributed to remodeling after myocardial infarction 
developed by coronary ligation in pigs. Cardiac 
remodeling is reduced by the angiotensin converting 
enzyme inhibitors and AT1R blockers. It was suggested 
that the antihypertrophic effects of these drugs result not 
only from diminished AT1R stimulation but also from 
increased stimulation of growth-inhibitory AT2Rs.
19
 
In addition, the antihypertrophic AT2R mediated effect 
was also shown in gene-targeted mice, which revealed 
an antihypertrophic effect in cardiac remodeling after 
myocardial cryo-injury and link the expression of 
cardiac endothelial nitric oxide synthase (eNOS) to 
AT2R activation. This has been indicated by an 
increased heart weight/body weight ratio, a significant 
low level of eNOS; accompanied by a decrease in 
cardiac cGMP levels in AT2R-deficient mice compared 
with control mice.
20
 Moreover, a AT2R gene transfer 
study in spontaneously hypertensive rats (SHR) revealed 
that AT2R over expression attenuates cardiac 
hypertrophy, independent of a change in blood 
pressure.
21
 This beneficial outcome was marked by the 
decreased left ventricular wall thickness and heart 
weight to body weight ratio in AT2R treated SHRs 
compared with control animals. 
The functional role of AT2R was also revealed in vivo 
in rat’s heart in which AT2R played a role in the cardiac 
hypertrophic process by selectively regulating the 
expression of growth-promoting and growth-inhibiting 
factors.
22
 This result had been shown by a marked 
increase in the gene expression of c-fos, endothelin-1, 
and insulin-like growth factor-1 and atrial natriuretic 
peptide in Ang II–induced hypertension when AT2R is 
blocked by PD123319.  Contrary to the above studies, 
gene targeting in vivo study in mice indicated that left 
ventricular hypertrophy, impaired diastolic relaxation 
and cardiac fibrosis was higher in wild mice for AT2R 
than that of AT2R gene negative mice after Ang II–
infusion to induce hypertension.
23, 24
 
Cardiac protective roles of AT2R in 
myocardial infarction 
Different studies demonstrated the AT2R mediated 
protective role after the development of myocardial 
infarction. For instance the cardio protective role of 
AT1R blocker, candesartan, was shown to be mediated 
by AT2R, which was conducted in pigs.
25
 Candesartan 
reduced the infarct size in treated pigs compared to the 
control groups. In addition, pretreatment with AT2R 
antagonist abolished the reduction of infarct size by 
candesartan, which indicates the involvement of AT2R 
in cardiac protection. Furthermore, C21 reduced the post 
infarction size in treated Wistar rats compared to the 
control via AT2R mediated anti--inflammatory and 
antiapoptotic effects.
26
 Another study conducted in 
AT2R transgenic mice also improves the left ventricular 
function after myocardial infarction compared to the 
wild type mice. The result showed a higher in the 
ejection fraction and a smaller end-systolic volume 
index (ESVI) in transgenic mice than that of wild type; 
but there was no difference in the size of the infarct.
27 
Related studies had shown that AT2 receptor deficiency 
exacerbates short-term death rates and heart failure after 
experimental acute myocardial infarction AT2R 
knockout mice.
28,29
 These findings indicate the 
protective roles of AT2R in cardiovascular functions 
with different mechanisms as illustrated in figure 3. 
Effects of AT2R on renal system 
The renal AT1R and AT2R distribution was studied in 
the rat kidney using immune-histochemistry and RT-
PCR. AT1R translational sites were observed 
throughout the kidney, with the strongest labeling found 
in the vasculature of the renal cortex and the proximal 
tubules of the outer medulla. The AT2R protein 
expression was found throughout the rat kidney, 
although there was little to no expression found in the 
glomerulus and medullary thick ascending limbs of 
Henle (TAL).
30
 Another study revealed that AT2R was 
found on glomerular endothelial cells and tubular 
epithelial cells in the cortex, interstitial, and tubular cells 
in the outer medulla, and inner medullary collecting duct 
cells with no clear functions.
31
  
Roles in nephrogenesis 
As studied in the fetal lamb, both AT1R and AT2R were 
expressed early during nephrogenesis with specific 
spatial and temporal distribution during gestation.  
High-AT2R mRNA expression took place in the 
outermost nephrogenic area, in the undifferentiated 
mesenchymal cells and in differentiated epithelial cells 
of macula densa of maturing glomeruli. This may 
indicate that, AT2R in mesenchymal cells is involved in 
regulation of cell proliferation and apoptosis during the 
time of nephrogenesis.
32
 Another finding suggested that 
AT1R and AT2R are both involved in the modulation of 
development of the nephron, and that Ang II provides 
signals through both receptors. AT1R mainly stimulate 
cell proliferation but AT2R counter-regulates the AT1R 
mediated cell proliferation via inhibition of proliferation 
and apoptosis.
33
 The growth stimulating effect of AgII 
on embryonic renomedullary interstitial cells which is 
mediated by AT1R is also regulated by its anti-
proliferative effects mediated by AT2R.
34
  
AT2R mediated natriuresis effect 
The RAS plays various roles in the regulation of the 
homeostasis of blood composition and volume which in 
turn determines the blood pressure via AT1R. The renal 
role of AT2R in hypertension is not yet clear though 
different studies showed its natriuretic effect. A study 
conducted on the AT2R knockout mice showed that the 
blood pressure was higher in AT2 receptor knockout 
mice than control. At same renal perfusion pressure, 
wild-type mice excreted more sodium and water than 
AT2R knocked out mice. In addition, renal microsomes 
from AT2R knocked out mice had less activity in 
hydroxylating arachidonic acid than controls, which 
may contribute to the intrarenal differences.
35
 This can 
indicate the importance of AT2R in regulation of blood 
pressure by modulating intra renal diuresis effect. 
Similar study coducted in AT2R gene lacking mice after 
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infusion of AgII was shown a marked and sustained 
increase in systolic blood pressure (SBP) and reduction 
in urinary sodium excretion, but neither SBP nor urinary 
sodium was changed in wild mice. In addition, the 
molecular mechanism of natriures effect of AT2R was 
related with the decrease in basal levels of renal 
interstitial fluid BK, and CGMP, an index of nitric oxide 




The AT2R mediated natriuretic effect was also studied 
in the streptozotocin induced rats in which the tubular 
expression of AT2R and its natriuretic effect was higher 
in diabetic rats compared to the control rats. The 
natriuretic effect was reduced by the administration of 
AT2R antagonist, PD-123319, associated with a 




The potential natriuresis effect of AT2R has also been 
observed by administering AT2R receptor agonist, C21, 
to obese Zucker rats. Infusion of C21 into rats under 
anesthesia caused a dose-dependent increase in urine 
flow and urinary Na volume which were blocked by pre-
infusion of the AT2R antagonist, PD123319. The 
excretion of sodium was not associated with the change 
in the glomerular filtration, indicating the tubular effect 
of C21. The diuresis and natriuresis effect was enhanced 
by the co-administration of amiliride, suggesting 
involvement of the AT2R. The involvement of AT2R in 
natriureis was associated with an increase in NO and 
cGMP.
38
 All of the above effects of AT2R agonist 
revealed that AT2R is mediating natriuresis via NO-
cGMP pathway. 
Moreover, the natriuresis effect of AT2R was 
potentiated by inhibition of NAD(P)H oxidase in a study 
conducted in Sprague-Dawley rats. Preinfusion of 
apocynin (NADPH oxidase inhibitor) had no effect on 
the net increase in urinary flow or urinary sodium rate in 
response to candesartan, however, it caused profound 
increases in CGP-42112A (AT2R agonist)-induced 
increase in urinary flow or urinary sodium rate and 
fractional excretion of Na. CGP-42112A infusion in the 
presence of apocynin increased urinary nitrite/nitrates 
and cGMP over basal, suggesting its signal transduction 
pathway. Based on the finding, NADPH oxidase may 
have an antagonistic role in AT2R mediated natriuresis/ 
diuresis possibly via neutralizing nitric oxide and 
thereby influence fluid-Na homeostasis.
39
 
Renal Protection Effects of AT2R 
The roles of AT2R in kidney disease protection are 
mediated via multitude of mechanisms, mainly by 
regulating the fibrosis, and inflammatory response as 
shown in the figure 3. The anti-fibrotic and anti-
inflammatory effects mediated by AT2R were observed 
in a study conducted in AT2R gene null mice with 
kidney disease induced by unilateral ureteral obstruct-
tion.
40
 The result of this study revealed that more severe 
fibrosis (with increased collagen) in interstitial cells of 
kidney of AT2R null mice was observed compared to 
the wild mice. In addition, though cell proliferation and 
macrophage infiltration were comparable, an increased 
level of fibroblasts and myofibroblasts were present in 
obstructed kidney of the AT2R null mice compared to 
that of wild mice. This indicates the protective role of 
AT2R in the remodeling of the kidney cell following an 
injury. The result of another study is consistent with the 
above study in which the role of AT2R was studied by 
administering PD-123319.  Treatment with PD-123319 
was found to exacerbate the increase in interstitial 
volume and collagen IV matrix score of the ureteral 
obstructed kidney.
41
 These results suggest that AgII 
operating through the AT2R exerts an antifibrotic effect 
on the kidney during obstructive nephropathy in 
opposition to the profibrotic effects of AgII acting 
through the AT1R. Interestingly, the AT2R agonist, 
CGP-42112A treatment in obese rats reduced the plasma 
and kidney cortex inflammatory (TNF-α, IL-6) and 
oxidative stress (gp-91
phox
) markers and increased 
plasma antioxidant activity to the levels seen in lean 
control rats.
39
 This indicates the importance of AT2R in 
reducing renal inflammation related to obesity caused 
hypertension. 
As mentioned earlier, the anti-inflammatory effects of 
renal proximal tubule AT2R has been associated with 
the increase in the anti-inflammatory interleukin-10 as 
studied in vivo and in vitro studies.
42
 Protective role of 
the AT2R in a renal wrap hypertension has been shown 
in one kidney wrap model of rats. In this study, PD 
123319, a specific AT2-receptor antagonist, signi-
ficantly increased SBP and decreased renal interstitial 
fluid (RIF), BK, nitric oxide metabolites (NOX), and 
cGMP in both kidneys. In contrast, losartan normalized 
SBP and increased renal function, RIF BK, NOX, and 
cGMP in contralateral kidneys.
36 
Role of AT2R on Nervous System 
The AT2R is not only limited to peripheral tissues, but 
also found in the brain with wide distribution. AT1R 
receptor subtypes in the brain is present in areas related 
to regulation of blood pressure, water intake (circum-
ventricular organs and paraventricular nucleus), and 
pituitary hormone secretion, and AT2R is found in 
different brain areas of which function has not been yet 
determined. 
 According to an in vitro study done from brain of adult 
and two week old rats, AT2R has been detected in 
lateral septum, subthalamlic nucleus, and inferior olive 
in both rats. AT2R was also found in thalamic nuclei, 




 cranial nerves, geniculate 
bodies, cerebellum, and cingulated cortex in brain of 
young rats.
44
 In addition, AT2R have been found in 
somato-dendrite parts of hypothalamus-paraventricular 
neurons expressing vasopressin and other neuromodu-
lators with a probable strategic position for surface 
activation by Ag II and/or intracellular trafficking.
45
 The 
increased expression of AT2R has been shown in 
hypothalamus  in the  SHR compared to that of  the 
normotensive Wistar- Kyoto rat (WKY)
46
, suggesting 
the  hyperactive RAS system in pathologic conditions. 
AT2R is also localized in sensory neurons of human 
dorsal root ganglion, and nerve fibers in peripheral 
nerves, skin, urinary bladder and bowel 
47
 which may 
indicates its involvement in nociception. 
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On top of these, a comparative in vitro study revealed 
that astrocyte cultures from neonatal rat brains contain 
predominantly AT1R that are coupled to a stimulation 
of inosito-phospholipid hydrolysis. In contrast, neuron 
cultures contain mostly AT2R that are coupled to a 
reduction in basal cGMP levels, but a smaller population 
of AT1R is also present in these neurons.
48 
 
Figure 3: Proposed AT2-R–mediated effects on cardiovascular and renal system.43 PP2A indicates serine/threonine phosphatase 2A; 
Ik, delayed rectifier K1 current; IA, transient outward K1 current; Ca+2/CaMK; calcium calmodulin kinase; MLCK, myosin light 
chain kinase; and EDHF, endothelium-derived hyperpolarizing factor. 
 
Neurite outgrowth and differentiation 
Functional studies in neuronal cells have demonstrated 
the capability of AT2R to modulate neuronal 
excitability, neurite elongation, and neuronal migration, 
which may be an important regulator of brain 
functions.
49
 An in vitro study conducted on cerebellar 
cell cultures revealed that AT2R activation by AgII 
enhanced cell differentiation, and involved in neurite 
outgrowth and cell migration (morphological 
differentiations), which are  important processes in the 
organization of the various layers of the cerebellum. 
Activation of AT2R by Ag II, in the presence of AT1R 
antagonist, has been associated with increased 
elongation of neurites and cell migration from the edge 
of the micro-explant toward the periphery. In addition, 
there were an increase in the expression of neuron-
specific bIII-tubulin, and expression of the microtubule-
associated proteins tau and MAP2 (proteins stabilizing 
the polymerized microtubules), indicating the 
involvement of AT2R in neuronal cell differentiation. 
These effects have been abolished when Ang II was co-
incubated with PD-123319 (AT2R antagonist).
50
 In 
addition, this study is consistent with another study 
showing the increase in neurite length and density when 





The functional role of AT2R in the prevention of 
neuronal injury related to stroke and ischemia has been 
elucidated by different investigations. A study conducted 
in AT2R negative and wild type mice demonstrated that 
AT2R stimulation has a protective effect on ischemic 
brain lesions, at least partly through the modulation of 
cerebral blood flow and superoxide production. After 
ischemia is induced by middle cerebral artery occlusion, 
the ischemic area, the neurological deficit was 
significantly larger in AT2R– deficient mice than in wild 
type mice.  Superoxide production and NADPH oxidase 
activity were enhanced in the ischemic area of the brain 
in the receptor deficient mice. Moreover, an AT1R 
blocker, valsartan, significantly inhibited the ischemic 
area, neurological deficit, and reduction of cerebral 
blood flow as well as superoxide production and 
NADPH oxidase activity in wild type mice, but these 
effects of valsartan were weaker in AT2R deficient 
ones.
52
 Moreover, AT1 Receptor blockade promotes the 
local AgII System in cerebral micro vessels in SHR 
compared to the control rats. The increased AT2R 
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expression and stimulation after administration of 
candesartan may contribute to the protection against 
brain ischemia and inflammation.
50,51
 
The direct neuroprotective effect of AT2R stimulation 
by intra cerebroventricularly administration of 
CGP42112 before stroke induction has been revealed by 
another study conducted in spontaneously hypertensive 
mice (SHM). Based on infarct, and behavioral data, 
CGP42112 dose-dependently reduced cortical infarct 
volume and motor deficit. In addition, there was an 
increased neuronal survival in the infarcted region.
53
 
similarly, centrally administered C21 to SMH before and 
after induction of stroke by middle cerebral endothelin 
confers neuroprotection against stroke damage.
54
 This 
benefit has been suggested to be likely to involve 
various mechanisms, including microglial activation of 
endogenous repair and enhanced cerebroperfusion. 
Similarly, in vitro study showed that AgII protected 
neuronal ischemic injury by activating AT2R in the 
cultured cortical neurons. After oxygen-glucose 
ischemia/reperfusion model, Ang II ameliorated the 
neuronal injury caused by oxygen-glucose deprivation 
and also increased cell viability through inhibiting cell 
apoptosis by reversing the increased Bax mRNA and the 
decreased Bcl2 mRNA expression. These protective 
activities of Ang II has been attenuated by co-treatment 
with AT2R blocker (PD123319)
55
, indicating the role of 
AT2R in neuroprotection after injury. 
The molecular mechanism of AT2R mediated 
neuroprotection may be related to the increased level of 
a neuroprotective factor, methyl methanesulfonate 
sensitive 2 (MMS2) as described by study in mice. 
According to this study, after mice underwent permanent 
middle cerebral artery occlusion, AT2R mRNA 
expression was significantly increased in the ischemic 
side of the brain. In ischemic brain regions, MMS2 was 
increased in wild-type mice, but not in AT2R knockout 
mice. This has been confirmed by administering 
Valsartan which enhanced MMS2 expression to a 
greater extent in wild-type mice compared to the AT2R 
knockout mice. To confirm the role of MMS2, 
intracerebroventricular administration of MMS2 siRNA 
showed more impaired avoidance rate after middle 
cerebral artery occlusion compared with that in control 
siRNA–transfected mice.56 This direct relationship 
between AT2R and MMS2 expression gives a clue for 
signal transduction of AT2R stimulation for 
neuroprotection via DNA repair mechanism following 
ischemia. In addition, the proangiogenic effect of AT1R 
antagonist in the endothelial cells of micro vessels in the 
brain may be related to the expression of BDNF via 




The neurodegenerative effect of AT2R oligomers has 
been described by a study using animal models of 
Alzheimer disease (AD). Neurodegeneration in AD 
correlates with dysfunction of diverse signal transduc-
tion mechanisms, such as the G-protein-stimulated 
phosphoinositide hydrolysis mediated by Gαq. It was 
stated that impaired Gαq-stimulated signaling in brains 
of AD patients and mice correlated with the appearance 
of cross linked oligomeric AT2R, sequestering Gαq. 
Amyloid β (Aβ) was causal to AT2R oligomerization, 
because cerebral microinjection of Aβ triggered AT2R 
oligomerization in the hippocampus of mice in a dose-
dependent manner. Aβ induced AT2 oligomerization by 
a two-step process of oxidative and transglutaminase-
dependent cross-linking. The induction of AT2 
oligomers in a transgenic mouse model with AD-like 
symptoms was associated with Gαq dysfunction and 
enhanced neurodegeneration. Vice versa, stereotactic 
inhibition of AT2 oligomers by RNA interference 
prevented the impairment of Gαq and delayed Tau 
phosphorylation. Thus, Aβ induces the formation of 
cross-linked AT2 oligomers that contribute to the 
dysfunction of Gαq in an animal model of Alzheimer 
disease.
58
This can lead to dysfunction of the cognitive 
function of the brain. 
In addition, the cognitive function of AT2R has been 
shown by neuroprotective study in the case of ischemic 
neuronal injury by using passive avoidance test to relate 
neuroprotection with cognitive function. According to 
this study, cognitive function was significantly impaired 
in AT2R null mice compared to that of the wild type 
mice. Treatment with valsartan prevented the cognitive 






AT2R mediates different regulatory effects in the 
cardiovascular, renal and nervous system through its 
anti-inflammatory, anti- proliferative, vasodilator and 
natriuresis actions, most of which are counter regulatory 
to the actions mediated by AT1R. The vasodilation, 
natriuresis and anti-inflammatory effects are very 
important actions to regulate and control the rise in 
blood pressure and the subsequent complications on the 
heart, blood vessels, kidney, brain and other end organs. 
Thus, the AT2R mediates the protective effects in 
cardiac, renal and brain injury induced by different 
factors. Most of the aforementioned actions mediated by 
AT2R involve the BK and/or NO-cGMP signal 
transduction pathways and accompanied by the 
production of inflammation protective factors like 
interleukin-10 and neuroprotective factors like MMS2 
and BDNF. Therefore, the development of AT2R 
agonist can be a potential target in the principle of 
prevention and treatment of hypertension, myocardial 
infarction, stroke and other organ diseases. In addition, 
further studies have to be conducted that can show the 
molecular signal transduction involving effects mediated 
by the AT2R.  
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